Advertisement

Rheumatology International

, Volume 27, Issue 1, pp 1–5 | Cite as

Cyclooxygenase-2 polymorphisms and risk of systemic lupus erythematosus in Koreans

  • Min-Young Her
  • Ahmed El-Sohemy
  • Marilyn C. Cornelis
  • Tae-Hwan Kim
  • Sang-Cheol BaeEmail author
Original Article

Abstract

Cyclooxygenase-2 (COX-2) is a key regulatory enzyme in the synthesis of prostanoids associated with trauma and inflammation. Upregulation of COX-2 in human lupus T cells resists anergy and apotosis. We investigated the COX-2 gene for functional variants that may influence susceptibility, clinical outcomes and severity of systemic lupus erythematosus (SLE) in a Korean population. The study included 345 patients with SLE and 400 unrelated healthy controls. Genotyping for the −765G → C polymorphism of COX-2 was performed by PCR–RFLP analysis. No difference in the distribution of the genotype frequencies between patients and controls was found. COX-2 genotypes were not associated with clinical features except hematologic abnormalities and anti-RNP antibody. We did not detect any association between COX-2 genotype and disease severity in SLE patients. These results suggest that the −765G → C polymorphism of COX-2 does not play a significant role in the development of SLE in a Korean population. A possible protective effect of the low activity C allele against the production of anti-RNP antibodies merits further investigation.

Keywords

Cyclooxygenase -2 Systemic lupus erythematosus Polymorphism 

Notes

Acknowledgments

This work was supported in part by a grant of the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (01-PJ3-PG6-01GN11-0002). We gratefully acknowledge Young-Hi Lee and Eun-Kyoung Ju for data collection and management and Jung-Ah Kim for DNA preparation.

References

  1. 1.
    Hoffman RW (2004) T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 113:4–13PubMedCrossRefGoogle Scholar
  2. 2.
    Green DR, Droin N, Pinkoski M (2003) Activation-induced cell death in T cells. Immunol Rev 193:70–81PubMedCrossRefGoogle Scholar
  3. 3.
    Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615–623PubMedCrossRefGoogle Scholar
  4. 4.
    Xu L, Zhang L, Yi Y, Kang HK, Datta SK (2004) Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 10:411–415PubMedCrossRefGoogle Scholar
  5. 5.
    Hamberg M, Samuelsson B (1973) Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci USA 70:899–903PubMedCrossRefGoogle Scholar
  6. 6.
    Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. Faseb J 12:1063–1073PubMedGoogle Scholar
  7. 7.
    Smith WL, Langenbach R (2001) Why there are two cyclooxygenase isozymes. J Clin Invest 107:1491–1495PubMedCrossRefGoogle Scholar
  8. 8.
    Tomasoni S, Noris M, Zappella S, Gotti E, Casiraghi F, Bonazzola S, Benigni A, Remuzzi G (1998) Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 9:1202–1212PubMedGoogle Scholar
  9. 9.
    Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, Remuzzi G (2001) Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 60:653–663PubMedCrossRefGoogle Scholar
  10. 10.
    Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, Takahashi E, Tanabe T (1994) Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 221:889–897PubMedCrossRefGoogle Scholar
  11. 11.
    Tsao BP (2004) Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol 16:513–521PubMedCrossRefGoogle Scholar
  12. 12.
    Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468–476PubMedGoogle Scholar
  13. 13.
    Humar B, Giovanoli O, Wolf A, Attenhofer M, Bendik I, Meier R, Muller H, Dobbie Z (2000) Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large swiss familial adenomatous polyposis kindred. Int J Cancer 87:812–817PubMedCrossRefGoogle Scholar
  14. 14.
    Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22:1631–1636PubMedCrossRefGoogle Scholar
  15. 15.
    Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M., Montali A, Campagna F, Ucchino S, Spigonardo F,Taddei S.Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A (2004) A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291:2221–2228PubMedCrossRefGoogle Scholar
  16. 16.
    Hochberg MC (1997) Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedGoogle Scholar
  17. 17.
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, ved O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Min-Young Her
    • 1
  • Ahmed El-Sohemy
    • 2
  • Marilyn C. Cornelis
    • 2
  • Tae-Hwan Kim
    • 1
  • Sang-Cheol Bae
    • 1
    Email author
  1. 1.Department of Internal Medicine, Division of Rheumatology, The Hospital for Rheumatic DiseasesHanyang University Medical CenterSeoulSouth Korea
  2. 2.Department of Nutritional SciencesUniversity of TorontoTorontoCanada

Personalised recommendations